SBIR and STTR Success Story for
Sarawak MediChem Pharmaceuticals, Inc.

(Information Posted/Updated on 07/04/2004)

Sarawak MediChem Pharmaceuticals, Inc.
1440 Davey Road
Woodridge, IL  60517

Contact:    Thomas M. Flavin
Phone:      630-739-9841
Fax:          630-739-6754

Related Award(s):  5R44 AIO34805-03
Technology Developed:
Calanolide A is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 and, as such, belongs to a highly favored drug class among practicing physicians who treat HIV patients, primarily because NNRTIs have longer-term therapeutic benefits over other drug classes.

Key Words:  HIV, Clinical Trials, NNRTI, resistance, in vitro, in vivo, calanolide, natural product.
Uses of Technology/Products/Service:
Calanolide A has a resistance profile that positions it well for rapid entry into the salvage treatment market for treatment-experienced patients, and also first- and second-line treatment strategies. In vitro studies show that Calanolide A remains active against many drug-resistant forms of HIV, while also interacting synergistically with other anti-HIV drugs, thereby positioning the drug well for future therapeutic combination treatments.

Benefit to Company:
Calanolide A is the Company's lead product. If It can become our Company's first commercialized product it will both help seriously ill patients improve their lives and will help the Company prosper.

How Product Was Commercialized:
Sarawak MediChem Pharmaceuticals has assembled a network of contract providers to assist in the preclinical and clinical development of calanolide A. This network has conducted the numerious preclinical laboratory and animal studies as well as the phase I human clinical trials necessary to test the safety of Calanolide A in humans. Our joint venture with the Malaysian Government has helped fund the development process.

Other Comments Related to Company's Success Story:
The potential sucess of Calanolide A is directly attributal to the NIH SBIR program. The program provided the means to develop this product in its early critical stages. Our collaboration with the National Cancer Institute has also been vital to the sucess of our program.

Past R&D and/or Sales from this Project:   $24,000,000
Estimated Future Annual R&D and/or Sales from this Project:   $40,000,000 R&D.